Reinhard Marks

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Viola Poeschel, Gerhard Held, Marita Ziepert et al. · The Lancet · 2019 · 253 citations · Full text

Medicine, Oncology, Cancer Immunology +10

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Gerhard Zugmaier, Nicola Gökbuget, Matthias Klinger et al. · Blood · 2015 · 161 citations · Full text

Medicine, Immunology, Oncology +16

Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting

Michael Lübbert, Hartmut Bertz, Ralph Wäsch et al. · Bone Marrow Transplantation · 2009 · 98 citations

Medicine, Oncology, Pharmacology +16

Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients

Michael Lübbert, Hartmut Bertz, Björn Rüter et al. · Bone Marrow Transplantation · 2009 · 89 citations

Medicine, Geriatric Medicine, Oncology +4

5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft

Juliane Steinmann, Hartmut Bertz, Ralph Wäsch et al. · Bone Marrow Transplantation · 2015 · 81 citations

Medicine, Oncology, Pharmacotherapy +9